Raymed Labs Ltd
Incorporated in 1994, Raymed Labs Ltd is in
the business of providing ophthalmological products[1]
- Market Cap ₹ 1.17 Cr.
- Current Price ₹ 2.75
- High / Low ₹ 2.75 / 2.08
- Stock P/E
- Book Value ₹ -5.73
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 28.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
0.03 | 0.03 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | 0.06 | 0.07 | 0.08 | 0.19 | 0.10 | 0.11 | |
Operating Profit | -0.03 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | -0.03 | -0.06 | -0.07 | -0.08 | -0.19 | -0.10 | -0.11 |
OPM % | |||||||||||||
-0.02 | -0.02 | 0.02 | 0.00 | -0.01 | -0.02 | -0.02 | 0.01 | 0.01 | 0.00 | 0.02 | 0.00 | 0.00 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
Profit before tax | -0.06 | -0.05 | -0.02 | -0.04 | -0.05 | -0.06 | -0.06 | -0.06 | -0.07 | -0.09 | -0.18 | -0.10 | -0.11 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
-0.07 | -0.05 | -0.02 | -0.04 | -0.05 | -0.06 | -0.05 | -0.06 | -0.07 | -0.08 | -0.17 | -0.10 | -0.11 | |
EPS in Rs | -0.16 | -0.12 | -0.05 | -0.09 | -0.12 | -0.14 | -0.12 | -0.14 | -0.16 | -0.19 | -0.40 | -0.23 | -0.27 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -17% |
TTM: | 21% |
Stock Price CAGR | |
---|---|
10 Years: | -8% |
5 Years: | 2% |
3 Years: | 41% |
1 Year: | 12% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 | 4.27 |
Reserves | -5.94 | -5.99 | -6.00 | -6.04 | -6.09 | -6.15 | -6.20 | -6.26 | -6.33 | -6.41 | -6.58 | -6.68 | -6.72 |
2.15 | 1.96 | 2.00 | 1.99 | 2.03 | 2.04 | 2.05 | 2.07 | 2.21 | 0.05 | 0.00 | 0.00 | 0.00 | |
0.04 | 0.06 | 0.04 | 0.06 | 0.07 | 0.11 | 0.14 | 0.18 | 0.10 | 2.33 | 2.47 | 2.56 | 3.60 | |
Total Liabilities | 0.52 | 0.30 | 0.31 | 0.28 | 0.28 | 0.27 | 0.26 | 0.26 | 0.25 | 0.24 | 0.16 | 0.15 | 1.15 |
0.24 | 0.20 | 0.20 | 0.19 | 0.19 | 0.18 | 0.17 | 0.17 | 0.16 | 0.16 | 0.15 | 0.15 | 0.14 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
0.28 | 0.10 | 0.11 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.08 | 0.01 | 0.00 | 1.01 | |
Total Assets | 0.52 | 0.30 | 0.31 | 0.28 | 0.28 | 0.27 | 0.26 | 0.26 | 0.25 | 0.24 | 0.16 | 0.15 | 1.15 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.04 | 0.11 | -0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.21 | -0.16 | -0.06 | |
0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.21 | 0.16 | 0.06 | |
0.00 | -0.17 | 0.03 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Net Cash Flow | -0.04 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | ||||||||||||
Inventory Days | ||||||||||||
Days Payable | ||||||||||||
Cash Conversion Cycle | ||||||||||||
Working Capital Days | ||||||||||||
ROCE % | -7.77% | -2.78% | -7.84% | -8.16% | -13.95% | -16.22% | -21.43% | -60.00% | -60.87% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Nov - Newspaper Publication for the Quarter and Half year ended 30 September 2024
-
Announcement under Regulation 30 (LODR)-Change in Management
6 Nov - Appointment of Mr. Nishant Bajaj and Ms. Roshni Kapshiwal.
-
Appointment of Company Secretary and Compliance Officer
6 Nov - Appointment of Mr. Nishant Bajaj and Ms. Roshni Kapshiwal.
-
Approval Of Unaudited Standalone Financial Results For The Quarter And Half Year Ended 30 September 2024
6 Nov - Board meeting outcomes and regulatory compliance updates.
- Approval Of Unaudited Standalone Financial Results For The Quarter And Half Yearly Ended 30 September 2024 6 Nov
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
RMIL manufactures formulations with advanced technologies focusing into Preservative free Ophthalmic dosage for Conjunctivitis and Glaucoma Patient care. It also manufactures other formulations which are converted from suspension to solution. Company has a range of over 80 products. It is a trademark owner of ophthalmic solution (eye drops), antioxidant capsules and tablets. RMIL is also into publication business.